# OnCo record ab-2100 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ab-2100/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ab-2100" ;
  schema:name "AB-2100"@en ;
  schema:alternateName "Integrated Circuit T cells"@en ;
  schema:description "AB-2100 is an experimental autologous Integrated Circuit T cell therapy, CRISPR-engineered, logic-gated CAR-T from Arsenal Biosciences, in phase 1 trials for clear-cell renal cell carcinoma; its current status is not stated."@en ;
  schema:url <https://onco.cc/drugs/ab-2100/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://arsenalbio.com/2024/04/30/arsenal-biosciences-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-ab-2100-in-development-as-a-treatment-for-clear-cell-renal-cell-carcinoma/>, <https://arsenalbio.com/2024/04/30/arsenal-biosciences-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-ab-2100-in-development-as-a-treatment-for-clear-cell-renal-cell-carcinoma/>, <https://arsenalbio.com/2026/08/31/arsenalbio-announces-new-focus-on-in-vivo-car-t-programs-to-leverage-investment-in-t-cell-engineering/>, <https://clinicaltrials.gov/api/v2/studies/NCT06245915>, <https://clinicaltrials.gov/search?intr=AB-2100> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Autologous Integrated Circuit T (ICT) cell therapy, CRISPR-engineered, logic-gated CAR-T" ;
  onco:cancers <https://onco.cc/cancers/clear-cell-rcc/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:companies <https://onco.cc/companies/arsenal-bio/> ;
  onco:trials <https://onco.cc/trials/nct06245915/> .